Pyrazole compounds as CCR1 antagonists
US8293917B2 · kind B2 · utility
7Cited by
32References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 1, 2009 |
| Grant date | Oct 23, 2012 |
| Priority date | — |
| Expiry date | Jul 27, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.